The vision of Numeric Biotech is to build an innovative portfolio of first-in-class treatments that target multiple mechanisms of age-related diseases including cancer. Our programs are based on cutting-edge research performed by Erasmus University Medical Center Rotterdam, The Netherlands.
Through linking a network of scientists and clinicians in internationally leading research institutes and hospitals, Numeric Biotech will drive its portfolio of ground-breaking therapies from laboratory to clinic.
These various collaborations with leading research institutes and clinics will give the company a firm basis in the new research paradigm of aging and age-related diseases.
Numeric Biotech has a highly experienced and dedicated leadership team with an outstanding track record of discovering and developing innovative medicines. The Numeric Biotech team members all have a longstanding history of successful drug launches and commercial success, both in a smaller biotechnology environment as well as at larger blue chip pharmaceutical companies.
The lead proprietary product of Numeric Biotech is FOXO4-DRI (NBT-103), of which the patent is pending. In high impact scientific papers, such as Cell, the product showed to be a first-in-class selective senolytic.